Thankyou for the updates AGM attendees.Putting delays aside, the...

Thankyou for the updates AGM attendees.

Putting delays aside, the state of play until the end of FY 2019 looks to have the potential to be vast in my opinion.

I beleive the potential announcements prior to end FY2019 to be as follows:

US Distribution partner signed for Vivagel BV;

FDA decision for Vivagel BV;

AZD0466 entering Phase 1;

DEP Irinotecan entering Phase 1;

DEP Doxetaxel completing first stage recruitment for monotherapy;

Vivagel BV launch in Europe by Mundipharma.

Bucket of just wait and see:

Fleurstat launch in ANZ by Aspen;

Further condom deals;

I feel if we get positive announcments for the items in bold over the next 1 to 2 months, Starpharma will be de-risked considerably and the valuations taken a lot more seriously.

I have a belief that bell potter will provide an updated guidance after the items in bold are resolved.